Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Director | July 14, 2026 | July 16, 2026 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | March 06, 2024 | March 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date July 14, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,043,661 |
Reported balance
After 2026-07-14 transaction · row 1
1 source rowRow 1 · 2026-07-14 · Purchase · Acquired 687,285 · Balance 2,043,661 |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.33 | Direct | 687,285 |
Reported balance
After 2026-07-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-14 · Purchase · Acquired 687,285 · Balance 687,285 F1: Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders. F2: The term of exercise is equal to five and one-half years after the Initial Exercise Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders.
F2: The term of exercise is equal to five and one-half years after the Initial Exercise Date.
Pacira BioSciences, Inc.
Report date March 06, 2024 · Filed March 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,127 |
Ending reported balance
After 2024-03-08 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-03-06 · Sale · Disposed 1,066 · Balance 140,384 Row 2 · 2024-03-07 · Sale · Disposed 28,257 · Balance 112,127 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.550 to $30.965, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2. Row 3 · 2024-03-08 · Sale · Disposed 90,000 · Balance 22,127 F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.300 to $30.860, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.550 to $30.965, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.300 to $30.860, inclusive.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RESMED INC
Report date July 24, 2019 · Filed July 24, 2019
Section 16 reporting ended · disclosed 2019-07-24. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2026 Filed Jul 16, 2026 20:03 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock Purchase Warrant · Derivative | 687,285 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001193125-26-306083 · ownership.xml · derivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 687,285 Underlying: Common Stock · 687,285 shares Expires not disclosed F1 · derivative.exercise_date: Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders. F2 · derivative.expiration_date: The term of exercise is equal to five and one-half years after the Initial Exercise Date. Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 20:03 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 687,285 | $1.46 | $999,999.68 |
DisclosureSEC source: 0001193125-26-306083 · ownership.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,043,661 Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 13:00 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 30,000 | $1.22 | $36,600.00 |
DisclosureSEC source: 0001184778-26-000009 · ownership.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,356,376 Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 01:30 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 40,565 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001184778-26-000007 · ownership.xml · derivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,104 Underlying: Common Stock · 40,565 shares Expires 2036-06-11 Read SEC document |
| July 30, 2025 Filed Jul 31, 2025 20:05 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 15,000 | $2.45 | $36,750.00 |
DisclosureSEC source: 0000950170-25-100882 · ownership.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By minor child Disclosed balance after: 1,345,676 Read SEC document |
| July 30, 2025 Filed Jul 31, 2025 20:05 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 275,000 | $2.45 | $673,750.00 |
DisclosureSEC source: 0000950170-25-100882 · ownership.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,330,676 Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 23:38 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 40,565 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001641172-25-016987 · ownership.xml · derivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,539 Underlying: Common Stock · 40,565 shares Expires 2035-06-26 Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 21:05 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 11,500 | $2.60 | $29,900.00 |
DisclosureSEC source: 0000950170-24-135767 · ownership.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By minor child Disclosed balance after: 1,059,376 Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 21:05 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 350,115 | $2.60 | $910,299.00 |
DisclosureSEC source: 0000950170-24-135767 · ownership.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,047,876 Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:09 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 29,700 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001628280-24-030640 · wk-form4_1719864535.xml · derivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,974 Underlying: Common Stock · 29,700 shares Expires 2034-06-27 Read SEC document |
| March 08, 2024 Filed Mar 8, 2024 22:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 90,000 | $30.60 | $2,754,000.00 |
DisclosureSEC source: 0001396814-24-000037 · wk-form4_1709937219.xml · nonDerivative · entry 3 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,127 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.300 to $30.860, inclusive. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 28,257 | $30.81 | $870,598.17 |
DisclosureSEC source: 0001396814-24-000037 · wk-form4_1709937219.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,127 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.550 to $30.965, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,066 | $29.67 | $31,628.22 |
DisclosureSEC source: 0001396814-24-000037 · wk-form4_1709937219.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,384 Read SEC document |
| December 19, 2023 Filed Dec 19, 2023 23:39 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 30,000 | $1.37 | $41,100.00 |
DisclosureSEC source: 0001628280-23-042045 · wk-form4_1703029177.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 697,761 Read SEC document |
| November 10, 2023 Filed Nov 14, 2023 21:24 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 22,950 | $0.98 | $22,491.00 |
DisclosureSEC source: 0001628280-23-038955 · wk-form4_1699997066.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667,761 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.95 to $1.01. Full information regarding the number of shares purcahsed at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:04 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 27,700 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001628280-23-022734 · wk-form4_1687295080.xml · derivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,274 Underlying: Common Stock · 27,700 shares Expires 2033-06-15 Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:36 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 12,925 | $0.00 Strike: $38.74 | $0.00 |
DisclosureSEC source: 0001209191-23-038025 · doc4.xml · derivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,925 Underlying: Common Stock · 12,925 shares Expires 2033-06-14 Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:36 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038025 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,450 F1 · shares: Represents restricted stock units that vest on June 3, 2024, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:53 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $29.90 | $0.00 |
DisclosureSEC source: 0001209191-23-029616 · doc4.xml · derivative · entry 3 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2023-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on July 12, 2013. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:53 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 5,015 | $41.78 | $209,526.70 |
DisclosureSEC source: 0001209191-23-029616 · doc4.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,675 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.75 to $41.85, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:53 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,000 | $29.90 | $209,300.00 |
DisclosureSEC source: 0001209191-23-029616 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 12:37 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 150,000 | $1.71 | $256,500.00 |
DisclosureSEC source: 0001628280-22-025100 · wf-form4_166359103116463.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,811 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.65 to $1.78. Full information regarding the number of shares purcahsed at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,225 | $0.00 Strike: $59.39 | $0.00 |
DisclosureSEC source: 0001209191-22-035227 · doc4.xml · derivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,225 Underlying: Common Stock · 8,225 shares Expires 2032-06-08 Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035227 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,690 F1 · shares: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 19:11 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 26,800 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001628280-22-005854 · wf-form4_164702588154244.xml · derivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,574 Underlying: Common Stock · 26,800 shares Expires 2032-03-09 Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-22-016876 · doc4.xml · derivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on July 5, 2012. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,000 | $10.81 | $75,670.00 |
DisclosureSEC source: 0001209191-22-016876 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,166 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-22-014267 · doc4.xml · derivative · entry 10 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,166 shares Expires 2022-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on April 3, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 193 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-22-014267 · doc4.xml · derivative · entry 9 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 193 shares Expires 2022-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on May 3, 2012. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,359 | $67.75 | $92,072.25 |
DisclosureSEC source: 0001209191-22-014267 · doc4.xml · nonDerivative · entry 6 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,530 Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 1,166 | $11.02 | $12,849.32 |
DisclosureSEC source: 0001209191-22-014267 · doc4.xml · nonDerivative · entry 5 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 193 | $11.02 | $2,126.86 |
DisclosureSEC source: 0001209191-22-014267 · doc4.xml · nonDerivative · entry 4 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 23:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,834 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-22-014267 · doc4.xml · derivative · entry 8 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,166 Underlying: Common Stock · 18,834 shares Expires 2022-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on April 3, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 23:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,807 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-22-014267 · doc4.xml · derivative · entry 7 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193 Underlying: Common Stock · 9,807 shares Expires 2022-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on May 3, 2012. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 23:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 28,641 | $66.83 | $1,914,078.03 |
DisclosureSEC source: 0001209191-22-014267 · doc4.xml · nonDerivative · entry 3 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,530 F1 · price: he price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.750 to $67.155, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 23:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 18,834 | $11.02 | $207,550.68 |
DisclosureSEC source: 0001209191-22-014267 · doc4.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 23:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 9,807 | $11.02 | $108,073.14 |
DisclosureSEC source: 0001209191-22-014267 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 21:54 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 30,000 | $6.75 | $202,500.00 |
DisclosureSEC source: 0001628280-21-019057 · wf-form4_163234764145489.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,811 Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:13 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 22,000 | $0.00 Strike: $7.98 | $0.00 |
DisclosureSEC source: 0001628280-21-012176 · wf-form4_162370157658233.xml · derivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,774 Underlying: Common Stock · 22,000 shares Expires 2031-06-10 Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 7,626 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0001209191-21-040097 · doc4.xml · derivative · entry 3 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,626 Underlying: Common Stock · 7,626 shares Expires 2031-06-09 Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040097 · doc4.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,530 F1 · shares: Represents restricted stock units that vest on June 3, 2022, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 13, 2021 Filed Jun 12, 2021 00:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GiftCommon Stock | 1,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040097 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,464 Read SEC document |
| March 23, 2021 Filed Mar 24, 2021 14:27 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 2,500 | $10.31 | $25,775.00 |
DisclosureSEC source: 0001628280-21-005426 · wf-form4_161659603050590.xml · nonDerivative · entry 3 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,811 Read SEC document |
| March 23, 2021 Filed Mar 24, 2021 14:27 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 2,500 | $10.21 | $25,525.00 |
DisclosureSEC source: 0001628280-21-005426 · wf-form4_161659603050590.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,311 Read SEC document |
| March 23, 2021 Filed Mar 24, 2021 14:27 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 5,000 | $10.20 | $51,000.00 |
DisclosureSEC source: 0001628280-21-005426 · wf-form4_161659603050590.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,811 Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 15:34 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 2,000 | $10.54 | $21,080.00 |
DisclosureSEC source: 0001628280-21-005156 · wf-form4_161616808093613.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,811 Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 15:34 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 1,000 | $10.58 | $10,580.00 |
DisclosureSEC source: 0001628280-21-005156 · wf-form4_161616808093613.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,811 Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 01:46 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 1,500 | $9.27 | $13,897.50 |
DisclosureSEC source: 0001628280-21-003990 · wf-form4_161490878112223.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,811 Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 21:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $16.67 | $0.00 |
DisclosureSEC source: 0001209191-20-052360 · doc4.xml · derivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2022-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested and became exercisable as to 25% of the shares on August 17, 2013 and as to the remaining shares over 36 months in successive equal monthly installments. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 21:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 70,000 | $16.67 | $1,166,900.00 |
DisclosureSEC source: 0001209191-20-052360 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.